MUMBAI, India, Sept. 28 -- Intellectual Property India has published a patent application (202527121719 A) filed by Jiangsu Hengrui Pharmaceuticals Co. , Ltd.; and Shanghai Hengrui Pharmaceutical Co. , Ltd. on December 04, 2025, for Anti-Npr1 Antibody And Pharmaceutical Use Thereof.
Inventors include Ying, Hanxiao; Shi, Jinping; Xu, Yingxia; Jin, Xinsheng; and Li, Xun.
The application for the patent was published on September 25, 2026, under issue no. 39/2026.
Abstract: Provided are an anti-NPR1 antibody, a pharmaceutical composition comprising the antibody, and an immunoconjugate. Also provided are an isolated nucleic acid encoding the NPR1 antibody, a host cell comprising the isolated nucleic acid, a method for using the NPR1 antibody to detect an NPR1 peptide or a fragment thereof in a sample, and a method for using the NPR1 antibody, the pharmaceutical composition, and the immunoconjugate for treating, preventing or ameliorating diseases or conditions related to NPR1, the diseases or conditions related to NPR1 comprising hypertension.
Disclaimer: Curated by HT Syndication.
